These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 4827071)

  • 61. Halothane-caffeine contracture testing in neuromuscular diseases.
    Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
    Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The in vitro determination of susceptibility to malignant hyperthermia.
    Iaizzo PA; Lehmann-Horn F
    Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Calcium uptake by isolated sarcoplasmic reticulum: examination of halothane inhibition, pH dependence, and Ca2+ dependence of normal and malignant hyperthermic human muscle.
    Blanck TJ; Gruener R; Suffecool SL; Thompson M
    Anesth Analg; 1981 Jul; 60(7):492-8. PubMed ID: 7195664
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Malignant hyperthermia.
    Byrd JP
    South Med J; 1983 Jul; 76(7):890-3. PubMed ID: 6346509
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of a commercial creatine kinase screening test for malignant hyperthermia (porcine stress syndrome).
    McDonell WN; Seeler DC; Basrur PK
    Can J Vet Res; 1986 Oct; 50(4):494-501. PubMed ID: 3791075
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Isoenzymes of creatine phosphokinase in serum of families with malignant hyperpyrexia.
    Meltzer HY; Hassan SZ; Russo P; Cho HW
    Anesth Analg; 1976; 55(6):797-9. PubMed ID: 1033694
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Electrodiagnostic tests in the detection of malignant hyperthermia.
    Eng GD; Becker MJ; Muldoon SM
    Muscle Nerve; 1984 Oct; 7(8):618-25. PubMed ID: 6543907
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Creatine phosphokinase (CPK) levels in pregnancy: a case report and a discussion of the value of CPK levels in the prediction of possible malignant hyperpyrexia.
    Isherwood DM; Ridley J; Wilson J
    Br J Obstet Gynaecol; 1975 Apr; 82(4):346-9. PubMed ID: 1125158
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Malignant hyperthermia.
    Blanck TJ; Gruener RP
    Biochem Pharmacol; 1983 Aug; 32(15):2287-9. PubMed ID: 6349642
    [No Abstract]   [Full Text] [Related]  

  • 70. Malignant hyperthermia.
    Rosenberg H
    Hosp Pract (Off Ed); 1985 Mar; 20(3):139, 144-5, 148 passim. PubMed ID: 3932397
    [No Abstract]   [Full Text] [Related]  

  • 71. Calcium and magnesium contents of malignant hyperpyrexia-susceptible human muscle.
    Bennett D; Cain PA; Ellis FR; Louis CF; Stanton M
    Br J Anaesth; 1977 Oct; 49(10):979-82. PubMed ID: 921875
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Suspected malignant hyperthermia in a strabismus patient. A case report.
    Dodd MJ; Phattiyakul P; Silpasuvan S
    Arch Ophthalmol; 1981 Jul; 99(7):1247-50. PubMed ID: 7259598
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Letter: Serum creatine phosphokinase and malignant hyperpyrexia.
    Ryan DW; Appleyard TN
    Br Med J; 1976 Jan; 1(6001):96. PubMed ID: 1244960
    [No Abstract]   [Full Text] [Related]  

  • 74. The genetic background to malignant hyperpyrexia revealed by serum creatine phosphokinase estimations in asymptomatic relatives.
    Isaacs H; Barlow MB
    Br J Anaesth; 1970 Dec; 42(12):1077-84. PubMed ID: 5504449
    [No Abstract]   [Full Text] [Related]  

  • 75. Malignant hyperpyrexia.
    Relton JE; Britt BA; Steward DJ
    Br J Anaesth; 1973 Mar; 45(3):269-75. PubMed ID: 4581791
    [No Abstract]   [Full Text] [Related]  

  • 76. An evaluation of the possible association of malignant hyperpyrexia with the Noonan syndrome using serum creatine phosphokinase levels.
    Hunter A; Pinsky L
    J Pediatr; 1975 Mar; 86(3):412-5. PubMed ID: 1113229
    [No Abstract]   [Full Text] [Related]  

  • 77. Letter: Serum creatine phosphokinase and malignant hyperpyrexia.
    Ellis FR; Clarke IM; Modgill EM; Currie S; Harriman DG
    Br Med J; 1976 Mar; 1(6009):584. PubMed ID: 1260292
    [No Abstract]   [Full Text] [Related]  

  • 78. Malignant hyperpyrexia and Duchenne muscular dystrophy: A case report.
    Oka S; Igarashi Y; Takagi A; Nishida M; Sato K; Nakada K; Ikeda K
    Can Anaesth Soc J; 1982 Nov; 29(6):627-9. PubMed ID: 6215975
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Screening for malignant hyperpyrexia.
    Bradley WG; Murchison D
    Br Med J; 1972 Oct; 4(5832):108-9. PubMed ID: 5077443
    [No Abstract]   [Full Text] [Related]  

  • 80. Letter: Serum creatin phosphokinase and malignant hyperpyrexia.
    Denborough MA
    Br Med J; 1975 Nov; 4(5993):408. PubMed ID: 1192097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.